Marie-Pierre Fort is an expert in Hematology at Institut Bergonié (France). Marie-Pierre Fort has authored 15 publications, the most recent in 2021. SLR score: 29 (community average: 125). How the SLR is computed.

LeadR Profile

Marie-Pierre Fort Institut Bergonié France
29 ScienceLeadR Reputation 29
Network Map

Hematology

Subspecialties:

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2008 - 2021

Source: PubMed

Institut Bergonié

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 15

Citations

Citations: 206 1st author: 0 Last author: 0 Unique author: 0


Best Journals

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Relevance of treatment-free remission recommendations in chronic phase chronic leukemia patients treated with frontline tyrosine kinase inhibitors.
PMID 33988316 — protein-tyrosine kinases, therapeutics, neoplasms, leukemia, myeloid, chronic-phase
Cancer Med20216
A single center evaluation of cost savings related to treatment-free remission in chronic myeloid leukemia patients: the prerequisites of a pharmaco-economy larger study.
PMID 32043283 — hematology, leukemia, myelogenous, chronic, bcr-abl positive, therapeutics, leukemia, myeloid, cost savings
Br J Haematol20202
Incidences of Deep Molecular Responses and Treatment-Free Remission in de Novo CP-CML Patients.
PMID 32899879 — incidence, leukemia, myelogenous, chronic, bcr-abl positive, therapeutics, leukemia, myeloid, chronic-phase
Cancers (Basel)202016
Incidence and outcome of BCR-ABL mutated chronic myeloid leukemia patients who failed to tyrosine kinase inhibitors.
PMID 31350815 — protein-tyrosine kinases, genes, abl, incidence, leukemia, myelogenous, chronic, bcr-abl positive, neoplasms, mutation, leukemia, myeloid, chronic-phase
Cancer Med201919
CML patients show sperm alterations at diagnosis that are not improved with imatinib treatment.
PMID 27501271 — diagnosis, therapeutics, spermatozoa, leukemia
Leuk Res201615

LeadR Networks

Main global connection map